Medication info

Samsung Sitagliptin Plus Tablet 50/850mg

Prescription medicationApproval withdrawn
Ingredient · strength
Sitagliptin Phosphate Hydrate›Strength being verifiedMetformin Hydrochloride›Strength being verified
Manufacturer / importer
Samsung Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
28 tablets/bottle, 30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 201603429 · Approved 2016.06.14

This product's status changed to Approval withdrawn on 2023.08.11. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, 'Patients who must not use this medicine' under Precautions for Use). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial metformin dose should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, 'General Precautions' under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, 'Patients who must not use this medicine' under Precautions for Use).

Ingredients

Manufacturer
Samsung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise to assist in the control of blood sugar in patients with type 2 diabetes. It is effective for those who are starting diabetes medication for the first time or those who have difficulties controlling blood sugar with existing monotherapy. This medication can be used instead of combining Metformin or Sitagliptin monotherapy when those are insufficient. It can also be combined with Metformin and sulfonylurea therapy, thiazolidinedione therapy, and insulin therapy in patients who have difficulties controlling blood sugar as well. It is used to improve blood sugar control in conjunction with various treatment methods.

Dosage and Administration

Adult dosage

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, 'Patients who must not use this medicine' under Precautions for Use). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial metformin dose should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, 'General Precautions' under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, 'Patients who must not use this medicine' under Precautions for Use).

Precautions

This medication is used for the treatment of diabetes and contains two active ingredients, Sitagliptin and Metformin. While taking this medication, serious allergic reactions may occur, so discontinue use and consult a healthcare professional immediately if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur. There is a risk of acute pancreatitis; if severe abdominal pain, nausea, vomiting, or fever occurs, one should go to a hospital immediately. The Metformin component can rarely cause lactic acidosis, a serious metabolic problem, so it’s important to inform medical personnel if symptoms like muscle pain, weakness, shortness of breath, or abdominal pain occur. Patients with poor kidney function or severe diseases such as serious infections, dehydration, heart failure, or acute myocardial infarction should not take this medication; its use should also be temporarily suspended before and after radiographic examinations that involve contrast agents. It is generally not recommended for use in pregnant or potentially pregnant women, nursing mothers, and children under 18 years of age. While on this medication, it's important to maintain a regular diet and exercise and to be aware of symptoms of hypoglycemia. When taken with insulin or other hypoglycemic agents, the risk of hypoglycemia may increase, so immediate measures should be taken if symptoms occur. This medication may affect liver and kidney function, so regular blood tests and kidney function tests are important. Additionally, alcohol consumption may increase the risk of side effects from this medication, so it is advisable to avoid alcohol while taking it. Patients scheduled for surgery or those with serious infections, trauma, or poor health should temporarily suspend use of this medication and resume once their condition improves. In the case of overdose, seek medical attention immediately, as this medication can be partially removed by hemodialysis. If blisters, severe joint pain, itching, or the like occur during treatment with this medication, inform your doctor immediately and seek treatment. Lastly, regular monitoring of blood sugar, kidney function, and hematological parameters is essential to safely continue treatment.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 31 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and debilitating arthralgia
  • blistering dermatitis herpetiformis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzymes
  • acute renal failure
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • itching
  • constipation
  • gastrointestinal gas distention
  • abdominal discomfort
  • indigestion
  • asthenia
  • severe hypoglycemia
  • anorexia
  • weight loss
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air entry, at room temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

28 tablets/bottle, 30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.